Nonsteroidal anti-inflammatory drug

Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX

Retrieved on: 
Freitag, November 11, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, ACR, FDA, Arthritis, Bleeding, Nonsteroidal anti-inflammatory drug, Trémeau, Pain, Tmax, Perception, 2021 Essex County Council election, Degenerative disease, TRM, NSAID, CV, View, Risk, Pain management, Patient, Chronic pain, Gastrointestinal bleeding, American College, Bleeding time, Traffic barrier, Medication, Pharmaceutical industry, Generic drug, Rheumatology, Rofecoxib

Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.

Key Points: 
  • Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.
  • These patients are often left with the inadequate options of living with pain, or resorting to opioids for pain relief.
  • Tremeau is developing TRM-201 (rofecoxib), a COX-2 selective NSAID, as a potential treatment option for people living with pain whose needs are not satisfied by traditional NSAIDs, Dr. Boice added.
  • VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005054/en/

Further Education Needed for the Proper Diagnosis of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the EU5, Spherix Global Insights Reports

Retrieved on: 
Donnerstag, November 10, 2022
HCP, Dermatology, Prevalence, MRI, MOA, Ankylosing spondylitis, EULAR, Spondyloarthropathy, Nephrology, Nonsteroidal anti-inflammatory drug, Education, Axial spondyloarthritis, Diagnosis, Ophthalmology, Magnetic resonance imaging, Gastroenterology, United Kingdom, X-ray, Rheumatology, JAK, Awareness, Patient, Physician, AS, TNF, Neurology, Medical imaging, Medical device, Pharmaceutical industry

EXTON, Pa., Nov. 10, 2022 /PRNewswire/ -- Rheumatologists in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) recognize a disconnect in the diagnosis and referral process for ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients. The lack of education, awareness of symptoms, and necessary tools needed to properly diagnose these patients has delayed referrals from primary care physicians to rheumatologists.

Key Points: 
  • The lack of education, awareness of symptoms, and necessary tools needed to properly diagnose these patients has delayed referrals from primary care physicians to rheumatologists.
  • Rheumatologists rely on a number of tests and imaging to diagnosis suspected axSpA (axial spondyloarthritis) patients under their care most notably the use of X-rays and MRIs.
  • In fact, only one-quarter of AS patients were referred with the correct diagnosis, which dropped to one-tenth among those with nr-axSpA.
  • To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter .

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

Retrieved on: 
Dienstag, November 1, 2022
Olive, Security (finance), THC, Depression, Nature, National Research Council, Food and Chemical Toxicology, Cannabinol, Assay, Inflammation, U.S. Securities and Exchange Commission, GBLX, CBC, Chaminade University of Honolulu, CBDV, Good manufacturing practice, Biomarker, Clinical trial, GLOBE, Parkinson's disease, Hospital, COVID-19, Immune system, Michigan State University, CBN, Cannabinoid, Terpene, Anxiety, University, Cannabidiol, Company, CBG, Prevalence, Cytokine release syndrome, Contract, Sativum, OTCQB, Chronic pain, Nonsteroidal anti-inflammatory drug, Pharmaceutical industry, CBD, Cannabis

Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences.

Key Points: 
  • Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences.
  • Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies.
  • Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada.

Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary

Retrieved on: 
Mittwoch, November 2, 2022
Biotechnology, Medical Devices, Health, Pharmaceutical, Dental, Ulcer, Inflammation, News, Inflammatory bowel disease, Bleeding, Antibe Therapeutics, TSX, Sale, Pain, Company, Risk, Nonsteroidal anti-inflammatory drug, OTCQX, Forward-looking statement, Hydrogen sulfide, Extrapyramidal system, Achievement, Pharmaceutical industry

Importantly, it provides non-dilutive funding for our pipeline and fortifies our already strong balance sheet.

Key Points: 
  • Importantly, it provides non-dilutive funding for our pipeline and fortifies our already strong balance sheet.
  • And of course, we wish the Citagenix and HANSAmed team the very best.
  • Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions.
  • The Companys anticipated next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.

NEXGEL Reports Positive Results from Proof-of-Concept Study for its Diclofenac Hydrogel Pain Treatment

Retrieved on: 
Dienstag, Oktober 25, 2022
Time, Intention, Securities Exchange Act of 1934, NASDAQ, Securities Act of 1933, Private Securities Litigation Reform Act, Efficiency, GLOBE, Skin, Nature, Annual report, Pain, Arthralgia, COVID-19, Technology, Diclofenac, Gel, Company, Nonsteroidal anti-inflammatory drug, Arthritis, SEC, Risk, Myalgia, Cosmetics

LANGHORNE, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NEXGEL or the Company) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today positive results from its proof-of-concept study for its diclofenac hydrogel patches.

Key Points: 
  • LANGHORNE, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (NEXGEL or the Company) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today positive results from its proof-of-concept study for its diclofenac hydrogel patches.
  • The patches are designed to treat pain indications such as arthritis, joint pain, muscle aches and more.
  • The study compared NEXGELs diclofenac hydrogel patches with the leading commercially available topical treatment.
  • The results revealed NEXGELs diclofenac hydrogel patches delivered an equivalent dose considerably faster and are longer-acting compared to the current standard-of-care, on a head-to-head basis.

Insights on the Analgesics Global Market to 2030 - Featuring Abbott Laboratories, AbbVie, Bayer and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Oktober 27, 2022
Health, Pharmaceutical, Analgesic, Cardiovascular disease, Growth, Administration, OTC, Paracetamol, Diclofenac, Pain, Sexual abuse, Opium, Investment, Population, CAGR, Nonsteroidal anti-inflammatory drug, Ibuprofen, Route of administration, Arthritis, Cancer, Therapy, ACHES, Coal, Pharmaceutical industry, Celecoxib

The global analgesics market was valued at $26,654.4 million in 2020, and is projected to reach $50,682.6 million by 2030, registering a CAGR of 6.6% during the forecast period 2021-2030.

Key Points: 
  • The global analgesics market was valued at $26,654.4 million in 2020, and is projected to reach $50,682.6 million by 2030, registering a CAGR of 6.6% during the forecast period 2021-2030.
  • Non-opioids, opioids, and compound analgesics (a combination of both, opioids and non-opioids) are the major analgesic products used globally.
  • However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are expected to restrain the growth of the global analgesics market.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Global Pain Management Drugs Market Demand and Pipeline Insights 2022 - ResearchAndMarkets.com

Retrieved on: 
Freitag, Oktober 21, 2022
Hospitals, Pharmaceutical, Health, API, Sale, Prevalence, Growth, Population, Inflammation, Cancer pain, Nonsteroidal anti-inflammatory drug, Narcotic, Research, Topical medication, Pain management, MEA, Hospital, Chronic pain, Cancer, Lists of diseases, Administration, Industry, Lists of countries and territories, Fever, Life expectancy, COVID-19, USD, Route of administration, Neuropathic pain, Intravenous therapy, Pharmaceutical industry, Medical device, Poultry, Dietary supplement, Paracetamol, Availability

The "Global Pain Management Drugs Market Demand and Pipeline Insights (2022 Edition) - Analysis By Drug Type, Route of Administration, End-Use, Availability, Sales Channel, By Region, By Country: Market Insights & Forecast with Impact of COVID-19 (2023-2028)" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pain Management Drugs Market Demand and Pipeline Insights (2022 Edition) - Analysis By Drug Type, Route of Administration, End-Use, Availability, Sales Channel, By Region, By Country: Market Insights & Forecast with Impact of COVID-19 (2023-2028)" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The global pain management drugs market is driven by an increasing number of Chronic Pain diseases and the prevalence of cancer pain worldwide.
  • This is likely to drive demand for many Pain Management drugs for advanced stages of cancer, chronic pain conditions and post-operative pain management drugs.
  • The report analyses the Pain Management Drugs Market by End use (Inflammation, Neuropathic Pain, Musculoskeletal Pain, Severe and Chronic Pain).

Global Veterinary Pain Management Market Report (2022 to 2027) - Increasing Popularity of Non-Conventional and Non-Pharmaceutical Treatment Techniques Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Freitag, Oktober 21, 2022
Pharmaceutical, Health, Veterinary, Laser, Hospital, Growth, Animal, CAGR, Arthralgia, Nonsteroidal anti-inflammatory drug, Laser medicine, Route of administration, Administration, Oral, Companion, Pain, Awareness, USD, Ownership, Dentistry, Pet, Pharmacy, Livestock, Cancer

In 2021, the opioids segment accounted for a second largest share of the veterinary pain management drugs market.

Key Points: 
  • In 2021, the opioids segment accounted for a second largest share of the veterinary pain management drugs market.
  • Based on types of veterinary pain management devices, the market is segmented into laser therapy and electromagnetic field therapy devices.
  • These advantages are expected to drive the growth of laser therapy devices in the veterinary pain management devices market.
  • The factors such as increasing number of veterinary surgeries, increasing pet insurance, increasing the demand of animal derived factors, and increasing veterinary hospitals and clinics are contributing the growth of China market in veterinary pain management market during forecast period.

AmTrust's Opioid-Use Reduction Program Improves Outcomes for Injured Workers

Retrieved on: 
Donnerstag, Oktober 20, 2022
Professional Services, Health, Insurance, Health Insurance, Human Resources, General Health, Doctor of Pharmacy, Insurance, CBT, Comp, Risk, Opioid, Review, Nonsteroidal anti-inflammatory drug, Program, Yoga, Drug, Multimedia, BOP, Paracetamol, Optum, Partnership, Cognitive behavioral therapy, Industry, Small business, AmTrust Bank, MED, Ibuprofen, Exercise, Pharmacy, Prescription, Health insurance

View the full release here: https://www.businesswire.com/news/home/20221020005968/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221020005968/en/
    AmTrust analyzed its workers' compensation claims paid by the company for the five-year period between 2017-2021.
  • In 2018, AmTrust formed a partnership with the pharmacy care management company, Optum Workers' Comp and Auto No-Fault (Optum), to reduce the amount of opioids prescribed to injured workers and the duration of opioid use.
  • We believe that our nurse prior-authorization program has helped reduce AmTrust's claims with opioids and long-term opioid dependency.
  • This has led to much better outcomes for injured workers, their families and their employers."

Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th

Retrieved on: 
Donnerstag, Oktober 20, 2022
Pharmaceutical, Health, Neurology, Feinberg School of Medicine, Bureau of Oceans and International Environmental and Scientific Affairs, Migraine, Risk, Practical Management of Pain, VP, Albany Medical Center, Traffic barrier, International Association for the Study of Pain, Bleeding time, Nonsteroidal anti-inflammatory drug, McMaster University Medical School, Pain management, Internal medicine, Chronic pain, History, Gastrointestinal bleeding, Trémeau, MD, National, Q&A, International Association, American Academy, Medication, KOL, NSAID, Stony Brook University, Albany Medical College, American Academy of Neurology, Pharmaceutical industry, Pain, Neurology

Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.

Key Points: 
  • Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.
  • In addition, Tremeaus Founder and CEO Bradford C. Sippy will discuss the companys development pipeline, including Phase III-ready TRM-201 (rofecoxib).
  • Previously marketed as VIOXX, rofecoxib has been shown to have a well-established efficacy profile in multiple indications, including migraine.
  • Tremeaus lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic with a well-established benefit-risk profile.